OTCMKTS:UCBJF UCB - UCBJF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. $78.95 0.00 (0.00%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$78.95▼$78.9550-Day Range$74.00▼$83.2052-Week Range$68.30▼$122.90VolumeN/AAverage Volume400 shsMarket Capitalization$14.92 billionP/E RatioN/ADividend YieldN/APrice Target$99.57 ProfileAnalyst RatingsChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest UCB MarketRank™ ForecastAnalyst RatingHold2.11 Rating ScoreUpside/Downside26.1% Upside$99.57 Price TargetShort InterestHealthy0.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth-1.07%From $4.66 to $4.61 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 stars 3.1 Analyst's Opinion Consensus RatingUCB has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 3 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $99.57, UCB has a forecasted upside of 26.1% from its current price of $78.95.Amount of Analyst CoverageUCB has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.30% of the outstanding shares of UCB have been sold short.Short Interest Ratio / Days to CoverUCB has a short interest ratio ("days to cover") of 2867, which indicates bearish sentiment.Change versus previous monthShort interest in UCB has recently decreased by 18.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUCB does not currently pay a dividend.Dividend GrowthUCB does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for UCBJF. Previous Next 2.8 News and Social Media Coverage News SentimentUCB has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.MarketBeat Follows2 people have added UCB to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UCB insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 10.48% of the stock of UCB is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for UCB are expected to decrease by -1.07% in the coming year, from $4.66 to $4.61 per share.Price to Book Value per Share RatioUCB has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About UCB (OTCMKTS:UCBJF) StockUCB SA engages in the research and development biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.Read More Receive UCBJF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Email Address UCBJF Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comUCB SA (OTCMKTS:UCBJF) Short Interest Down 18.7% in JanuaryOctober 20, 2022 | finance.yahoo.comUCB SA (UCBJF)February 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...April 25, 2022 | finance.yahoo.comHere's Why Momentum in UCB SA (UCBJF) Should Keep goingMarch 31, 2022 | msn.comWhat Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"March 25, 2022 | finanznachrichten.deUCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022February 7, 2022 | seekingalpha.comBiogen signs licensing deal with Xbrane for potential biosimilar to CimziaJanuary 23, 2022 | finance.yahoo.comZGNX Jan 2022 7.000 callFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 21, 2022 | msn.comWhy Zogenix Flew Higher Before Leveling Off This WeekJanuary 19, 2022 | markets.businessinsider.comUCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The HighlightsNovember 5, 2021 | finance.yahoo.comUCB Showcases Key Rheumatology Data at ACR Convergence 2021October 20, 2021 | finance.yahoo.comUCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy LabOctober 16, 2021 | msn.comBRIEF-UCB SA Gives An Update On U.S. FDA Review Of Biologics License Application (BLA) For BimekizumabSeptember 29, 2021 | finance.yahoo.comNew Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology CongressAugust 27, 2021 | benzinga.comWhy New Oriental Education Shares Are FallingAugust 12, 2021 | finance.yahoo.comSpectrumDNA, Inc. (SPXA)March 26, 2021 | finance.yahoo.comUCB SA/NV - Convening notice annual shareholders meetingFebruary 28, 2021 | seekingalpha.comUCB SA (UCBJF) CEO Jean-Christophe Tellier on Q4 2020 Results - Earnings Call TranscriptFebruary 23, 2021 | finance.yahoo.comUCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and DevelopmentJanuary 13, 2021 | finance.yahoo.comUCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of EpilepsyDecember 1, 2020 | finance.yahoo.comSpecifica Delivers Antibody Platform to UCB to Speed up Development of New TherapeuticsNovember 30, 2020 | finance.yahoo.comWorld's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19November 18, 2020 | finance.yahoo.comUCB unleashes the power of data in new collaborationNovember 17, 2020 | finance.yahoo.comUCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsyNovember 12, 2020 | seekingalpha.comUCB boosts gene therapy footprint with two new dealsNovember 12, 2020 | finance.yahoo.comUCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platformsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive UCBJF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Email Address UCBJF Company Calendar Today2/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:UCBJF CUSIPN/A CIK1290640 Webwww.ucb.com Phone(322) 559-9999Fax32-2559-9900Employees8,561Year Founded1928Price Target and Rating Average Stock Price Forecast$99.57 High Stock Price Forecast$111.00 Low Stock Price Forecast$86.00 Forecasted Upside/Downside+26.1%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.84 billion Price / Sales2.18 Cash Flow$7.67 per share Price / Cash Flow10.29 Book Value$52.49 per share Price / Book1.50Miscellaneous Outstanding Shares189,020,000Free FloatN/AMarket Cap$14.92 billion OptionableNot Optionable Beta0.55 Social Links Key ExecutivesJean-Christophe TellierChief Executive Officer & Executive DirectorSandrine DufourChief Financial Officer & Executive Vice PresidentIris Löw-FriedrichChief Medical Officer, EVP & Head-DevelopmentDhavalkumar PatelChief Scientific Officer & Executive VPKirsten Lund JurgensenExecutive VP, Head-Supply & Technology UnitKey CompetitorsViatrisNASDAQ:VTRSUnited TherapeuticsNASDAQ:UTHRTeva Pharmaceutical IndustriesNYSE:TEVAOno PharmaceuticalOTCMKTS:OPHLFSarepta TherapeuticsNASDAQ:SRPTView All Competitors UCBJF Stock - Frequently Asked Questions Should I buy or sell UCB stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" UCBJF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UCBJF, but not buy additional shares or sell existing shares. View UCBJF analyst ratings or view top-rated stocks. What is UCB's stock price forecast for 2023? 9 Wall Street research analysts have issued 1 year target prices for UCB's stock. Their UCBJF share price forecasts range from $86.00 to $111.00. On average, they expect the company's share price to reach $99.57 in the next year. This suggests a possible upside of 26.1% from the stock's current price. View analysts price targets for UCBJF or view top-rated stocks among Wall Street analysts. How have UCBJF shares performed in 2023? UCB's stock was trading at $80.40 at the beginning of the year. Since then, UCBJF stock has decreased by 1.8% and is now trading at $78.95. View the best growth stocks for 2023 here. Are investors shorting UCB? UCB saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 573,400 shares, a drop of 18.7% from the December 31st total of 705,700 shares. Based on an average daily trading volume, of 200 shares, the short-interest ratio is currently 2,867.0 days. View UCB's Short Interest. What is UCB's stock symbol? UCB trades on the OTCMKTS under the ticker symbol "UCBJF." How do I buy shares of UCB? Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is UCB's stock price today? One share of UCBJF stock can currently be purchased for approximately $78.95. How much money does UCB make? UCB (OTCMKTS:UCBJF) has a market capitalization of $14.92 billion and generates $6.84 billion in revenue each year. How many employees does UCB have? The company employs 8,561 workers across the globe. How can I contact UCB? UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The official website for the company is www.ucb.com. The company can be reached via phone at (322) 559-9999, via email at investor-relations@ucb.com, or via fax at 32-2559-9900. This page (OTCMKTS:UCBJF) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.